MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
Aspivix

Every year, 65 million obstetric and gynaecological treatments require access to the uterus. The standard use of Tenaculum forceps may be painful as well as traumatic and pose a risk of cross-contamination. Aspivix are developing a new generation of Tenaculum forceps which painlessly uses vacuum suction, reducing discomfort for the patient, eradicating the risk of bleeding and lesions and as a single use instrument avoids the risk of cross contamination.
In genecology, uterus access requires traumatic forceps. Aspivix, a new forceps gen using vacuum suction, eliminates pain, bleeding & lesion

Connect with Aspivix

Aspivix

2018

2018 Finalist Switzerland

Sub industry

Medical Devices

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.